- Home
- SGC vs FENC Comparison
SGC vs FENC Comparison
Compare SGC & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- FENC
- Stock Information
- Founded
- SGC 1920
- FENC 1996
- Country
- SGC United States
- FENC United States
- Employees
- SGC N/A
- FENC N/A
- Industry
- SGC Apparel
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGC Consumer Discretionary
- FENC Health Care
- Exchange
- SGC Nasdaq
- FENC Nasdaq
- Market Cap
- SGC 215.7M
- FENC 225.4M
- IPO Year
- SGC N/A
- FENC 2001
- Fundamental
- Price
- SGC N/A
- FENC $9.47
- Analyst Decision
- SGC Strong Buy
- FENC Strong Buy
- Analyst Count
- SGC 3
- FENC 2
- Target Price
- SGC $17.33
- FENC $13.50
- AVG Volume (30 Days)
- SGC 40.8K
- FENC 90.6K
- Earning Date
- SGC 11-05-2025
- FENC 11-06-2025
- Dividend Yield
- SGC 5.54%
- FENC N/A
- EPS Growth
- SGC N/A
- FENC N/A
- EPS
- SGC 0.52
- FENC N/A
- Revenue
- SGC $576,240,000.00
- FENC $33,302,000.00
- Revenue This Year
- SGC $1.76
- FENC $0.18
- Revenue Next Year
- SGC $3.37
- FENC $52.59
- P/E Ratio
- SGC $19.35
- FENC N/A
- Revenue Growth
- SGC 4.03
- FENC N/A
- 52 Week Low
- SGC $9.11
- FENC $3.96
- 52 Week High
- SGC $18.48
- FENC $9.92
- Technical
- Relative Strength Index (RSI)
- SGC 33.58
- FENC 58.05
- Support Level
- SGC $10.35
- FENC $8.26
- Resistance Level
- SGC $10.95
- FENC $9.92
- Average True Range (ATR)
- SGC 0.46
- FENC 0.39
- MACD
- SGC -0.13
- FENC 0.08
- Stochastic Oscillator
- SGC 9.95
- FENC 75.39
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.